To confirm that RIP2 phosphorylation and downstream NF‐κB and p38‐MAPK activation are dependent on NOD1, a selective NOD1 antagonist (ML130) was used to block this protein in THP‐1 cells before CRC‐EV (EV‐HT29, EV‐MC38) treatment. Here, NFKB1 is linked to colorectal carcinoma.